Portal de Periódicos da CAPES

Prognostic role of intratumoral IL-17A expression by immunohistochemistry in solid tumors: a meta-analysis

2017; Impact Journals LLC; Volume: 8; Issue: 39 Linguagem: Inglês

10.18632/oncotarget.18807

1949-2553

Shimin Wang, Zhian Li, Guoming Hu,

Breast Lesions and Carcinomas

// Shimin Wang 1 , Zhi’an Li 2 and Guoming Hu 3 1 Department of Nephrology, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, 312000, Zhejiang, China 2 Department of Surgical Oncology, Shaoxing Second Hospital, 312000, Zhejiang, China 3 Department of General Surgery, Breast and Thyroid Surgery, Shaoxing People’s Hospital, Shaoxing Hospital of Zhejiang University, 312000, Zhejiang, China Correspondence to: Guoming Hu, email: hgmplj@126.com Keywords: intratumoral IL-17A overexpression, immunohistochemistry, worse outcome, solid tumor, meta-analysis Received: February 06, 2017 Accepted: May 20, 2017 Published: June 29, 2017 ABSTRACT IL-17A is an important proinflammatory cytokine which is frequently elevated in tumor microenvironment. However, the role of intratumoral IL-17A in solid tumors remains controversial. Herein, we conducted a meta-analysis to assess the prognostic impact of intratumoral IL-17A in patients with solid tumor. PubMed and EBSCO were searched to identify the studies evaluating the associations between intratumoral IL-17A measured by immunohistochemistry (IHC) and overall survival (OS) and disease-free survival (DFS) in solid tumors. A total of 2972 patients with solid tumor from 21 published studies were incorporated into this meta-analysis. We found that high level of intratumoral IL-17A was significantly associated with worse 3-year, 5-year OS and 1-year, 3-year DFS, but not with 1-year OS or 5-year DFS in solid tumors. In addition, in stratified analyses by cancer types, IL-17A overexpression was significantly associated with worse OS in hepatic carcinoma, but with improved OS in esophageal squamous cell carcinoma (ESCC). Furthermore, high IL-17A expression positively correlated with advanced TNM stage. In conclusion, High expression of intratumoral IL-17A leads to an unfavorable clinical outcome in majority of solid tumors, implicating IL-17A is a valuable biomarker for prognostic prediction of human solid malignances and targeting it may have a potential for effective treatment.